Psychedelic Drugs Market

Psychedelic Drugs Market: Industry Trends and Global Forecasts, till 2030 - Distribution by Origin of Substance (Natural and Synthetic), Type of Psychedelic Substance (Gamma-hydroxybutyrate, Ketamine, MDMA, and Psilocybin), Target Disease Indications (Depression and Anxiety Disorders, Pain Disorders, Sleep Related Disorders and Trauma), Route of Administration (Oral, Intravenous, Intranasal and Sublingual) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,899

  • Companies Covered
    236

  • Pages
    280

  • View Count
    28989

Psychedelic Drugs Market Overview

The psychedelic drugs market is estimated to be worth over $6.5 billion in 2030 and is expected to grow at CAGR of 15% during the forecast period. Moreover, this condition along with other mental health disorders are estimated to be responsible for productivity associated losses worth over USD 1 trillion, every year, at the global level. In fact, the US reported a sharp increase (~20%) in number of prescriptions for antidepressants and anti-anxiety drugs during the global lockdown enforced to curb the spread of COVID-19.

According to the World Health Organization, the major roadblocks to effective treatment for depression and other mental illnesses include the lack of understanding of the aforementioned conditions resulting in an irrational social stigma, inaccurate diagnosis, and paucity of effective medication. In this context, it is worth highlighting that there is a growing body of clinical evidence supporting the therapeutic effect of psychedelic substances on psychiatric conditions, such as depressions. Experts in this field also believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications of the current pandemic. 

There are more than 300 Million Indiviaduals Suffering From Depression There is List of Psychedelic Therapy name in Global Psychedelic Therapeutics Market There are 44% depression and Anxiety disorder

Over time, it have been demonstrated that psychedelic substances interact with a variety of neurotransmitter pathways, including those of serotonin, acetylcholine, norepinephrine, and dopamine, among several others. In fact, there is evidence that an imbalance in the levels of serotonin in the brain, causes depression.  Similarly, the aforementioned biomolecules have been associated with a plethora of neurological conditions. As a result, biocompatible molecules having the ability to modulate neurotransmitter production / function, have the potential to be put to therapeutic use. Early in the 21st Century, XYREM®, a gamma-hydroxybutyric acid based psychedelic drug was approved for the treatment of cataplexy in patients suffering from narcolepsy. In 2019, SPRAVATO® (an analogue of ketamine), developed by Johnson and Johnson, was approved for use in patients suffering from treatment-resistant depression.  Recently, the US FDA granted the breakthrough drug designation to 3,4-Methylenedioxymethamphetamine (MDMA) and psilocybin, based on clinical evidence of these substances being capable of offering substantial therapeutic benefit in treating major depressive disorder, post-traumatic stress disorder and treatment resistant depression over other available therapies. Currently, several stakeholders in the pharmaceutical industry are actively evaluating the therapeutic potential of psychedelic substances against a wide array of mental health problems. As more players achieve proof-of-concept, this niche market is anticipated to witness substantial market growth in the mid-long term.

Key Companies in Psychedelic Drugs Market 

Examples of key psychedelic companies engaged in psychedelic drugs market (which have also been profiled in this market report; the complete list of psychedelic companies is available in the full report) include Celon Pharma, iX Biopharma, MAPS Public Benefit, MindMed, Janssen Pharmaceuticals and Jazz Pharmaceutical. This market report includes an easily searchable excel database of all the psychedelic companies developing psychedelic drugs, worldwide.

Scope of the Psychedelic Drugs Market Report

The “Psychedelic Drugs Market, 2020-2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market forecast, market outlook and future opportunities of the psychedelic drugs market. The market research report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in psychedelic drugs market.

15 Players are based in US. There are 544 Cumulative Number of Grants in 2020 There is 68 Players Based in North America

In addition to other elements, the market research report includes:

  • A detailed assessment of the current market landscape of psychedelic therapeutics, providing information on phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, type of psychedelic substance, origin of psychedelic substance, target therapeutic area route of administration (intranasal, intravenous, oral, sublingual, topical and transdermal), dosing frequency (single dose, twice a week, once in two months and others). In addition, it includes information on drug developer(s), highlighting year of their establishment, company size, and location of headquarters.
  • Tabulated profiles of prominent psychedelic therapeutics developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various psychedelic therapeutics, based on the various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population and geographical distribution of trials, study design, leading industry (in terms of number of trials conducted), study focus, target therapeutic area, key geographical regions.
  • An insightful analysis of clinical trial sites where the studies have been / are being conducted for evaluation of various psychedelic therapeutics, based on relevant parameters, such as type of psychedelic substance, trial phase, target therapeutic area and location of the trial.
  • A list of key opinion leaders (KOLs) within psychedelic drugs market, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to psychedelic drugs market. It also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn).
  • A detailed analysis of nearly 550 grants that have been awarded to research institutes engaged in psychedelic therapeutics projects, in the period between 2015 and 2020 (till May), including analysis based on important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, grant funding mechanism, study section involved, and recipient organizations. In addition, it highlights popular psychedelic therapeutics, popular funding institute centers, prominent program officers, and popular recipient organizations. 
  • An analysis of the partnerships that have been established in the recent past (2017-2020 till May), covering acquisitions and mergers, licensing agreements, product development agreements, research agreements, research and development agreements, clinical trial agreements, joint venture agreements and other relevant types of deals. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in psychedelic drugs market, highlighting the trend in the number of companies acquired between 2017-2020, based on parameters, such as year of merger and acquisition, type of acquisition, geographical location of the acquirer and the acquired company, and key value drivers. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
43% Partnership were Signed in 2020 71% mergers were done in north America A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.

The key objective of psychedelic drugs market report is to provide a detailed market analysis in order to estimate the existing market size, market trends, market value, statistics and future opportunity for psychedelics industry during the forecast period. Based on multiple parameters, such as target patient population, likely adoption and the annual treatment cost, we have provided informed estimates on the evolution of psychedelic therapeutics market for the forecast period 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] origin of substance (natural and synthetic) [B] type of psychedelic substance (gamma-hydroxybutyrate, Ketamine, MDMA, and psilocybin) [C] key geographical regions (North America, Europe, Asia Pacific and rest of the world) [D] target disease indications (depression and anxiety disorders, pain disorders, sleep related disorders and trauma)  and [E] route of administration (oral, intravenous, intranasal and sublingual). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in the market research report were also influenced by discussions held with multiple stakeholders in psychedelic drugs market. The market report features detailed transcripts of interviews held with the following individuals:

  • Andrew Chadeayne (Founder & Chief Executive Officer, CaaMTech)
  • Janakan Krishnarajah (Chief Operating Officer and Chief Medical Officer, iX Biopharma)
  • Alexander Speiser (Chief Operating Officer, Orthogonal Thinker)
  • Tracy Cheung, (Chief Communications Officer, COMPASS Pathways)
  • Benjamin Kelmendi (Yale University)

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are psychedelic drugs?

Answer: Psychedelic drugs or psychedelics belong to a class of hallucinogenic drugs having primary effect on the consciousness of the patient to treat a medical condition.

Question 2: How big is the psychedelic drugs market?

Answer: The psychedelic drugs market size is estimated to be worth $6.5 billion in 2030

Question 3: What is the projected market growth of the psychedelic drugs market?

Answer: The psychedelic drugs industry is expected to grow at compounded annual growth rate (CAGR) of XX% during the forecast period 2020 – 2030.

Question 4: Who are the leading companies in the psychedelic drugs market?

Answer: The leading companies in the psychedelic drugs market are Celon Pharma, iX Biopharma, MAPS Public Benefit, MindMed, Janssen Pharmaceuticals and Jazz Pharmaceutical.

Question 5: What is the psychedelic drugs market growth?

Answer: The global psychedelic drugs market size is estimated to be worth over $6.5 billion in 2030 and is expected to grow at CAGR of 15% during the forecast period 2020-2030.

Question 6: How much grant money has been received by the companies engaged in psychedelic drugs market?

Answer: Over USD 275 million of grant money has been received by the drug developers engaged in psychedelic drugs industry.

Question 7: How many companies are currently engaged in the psychedelic drugs market?

Answer: Over 45 companies are currently engaged in the psychedelic drugs industry.

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com